MIRCERA (methoxy polyethylene glycol-epoetin beta) is a synthetic form of erythropoietin, a hormone produced naturally by the kidneys to stimulate the production of red blood cells. It is designed for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients, including those on dialysis and those not on dialysis. MIRCERA works by binding to the erythropoietin receptor on bone marrow cells, thereby stimulating the production of red blood cells, which can help to alleviate the symptoms of anemia such as fatigue and weakness. It is administered via injection and is noted for its longer half-life compared to other erythropoiesis-stimulating agents (ESAs), allowing for less frequent dosing. As with any medication, it is important to use MIRCERA under the guidance of a healthcare professional to ensure its safe and effective use.